Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.97
(12.57%)
USD 1.97
(12.57%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | 35.64 Million USD | 513.14% |
| 2021 | -8.62 Million USD | -171.96% |
| 2020 | 11.98 Million USD | -16.24% |
| 2019 | 14.31 Million USD | -55.14% |
| 2018 | 31.9 Million USD | -38.58% |
| 2017 | 51.94 Million USD | -36.23% |
| 2016 | 81.45 Million USD | 3068.14% |
| 2015 | 2.57 Million USD | 114.3% |
| 2014 | -17.97 Million USD | -197.22% |
| 2013 | -6.04 Million USD | 68.79% |
| 2012 | -19.38 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | 5.16 Million USD | -10.19% |
| 2023 Q1 | 5.75 Million USD | -29.58% |
| 2022 Q1 | 44.05 Million USD | 811.07% |
| 2022 FY | 35.64 Million USD | 513.14% |
| 2022 Q2 | -9.45 Million USD | -121.45% |
| 2022 Q3 | -3.51 Million USD | 62.83% |
| 2022 Q4 | 8.16 Million USD | 332.42% |
| 2021 FY | -8.62 Million USD | -171.96% |
| 2021 Q3 | -5.62 Million USD | -255.65% |
| 2021 Q4 | -6.19 Million USD | -10.21% |
| 2021 Q2 | 3.61 Million USD | 957.96% |
| 2021 Q1 | -421 Thousand USD | -105.23% |
| 2020 Q3 | 7.05 Million USD | 2857.42% |
| 2020 Q1 | -2.87 Million USD | -385.67% |
| 2020 Q2 | -256 Thousand USD | 91.08% |
| 2020 Q4 | 8.05 Million USD | 14.14% |
| 2020 FY | 11.98 Million USD | -16.24% |
| 2019 Q2 | 6.72 Million USD | -25.05% |
| 2019 Q4 | 1 Million USD | 142.05% |
| 2019 Q3 | -2.39 Million USD | -135.54% |
| 2019 FY | 14.31 Million USD | -55.14% |
| 2019 Q1 | 8.97 Million USD | -28.73% |
| 2018 Q3 | 14.04 Million USD | 428.02% |
| 2018 Q2 | 2.65 Million USD | 1.64% |
| 2018 Q1 | 2.61 Million USD | -71.21% |
| 2018 FY | 31.9 Million USD | -38.58% |
| 2018 Q4 | 12.59 Million USD | -10.33% |
| 2017 Q4 | 9.08 Million USD | -41.13% |
| 2017 Q2 | 4.5 Million USD | -80.36% |
| 2017 Q1 | 22.92 Million USD | -59.99% |
| 2017 FY | 51.94 Million USD | -36.23% |
| 2017 Q3 | 15.43 Million USD | 242.68% |
| 2016 Q1 | -896 Thousand USD | -173.5% |
| 2016 Q4 | 57.3 Million USD | 379.43% |
| 2016 Q3 | 11.95 Million USD | -8.76% |
| 2016 Q2 | 13.09 Million USD | 1561.94% |
| 2016 FY | 81.45 Million USD | 3068.14% |
| 2015 Q4 | 1.21 Million USD | 111.99% |
| 2015 FY | 2.57 Million USD | 114.3% |
| 2015 Q3 | -10.16 Million USD | -24.34% |
| 2015 Q2 | -8.17 Million USD | -141.51% |
| 2015 Q1 | 19.69 Million USD | 457.74% |
| 2014 Q3 | -9.1 Million USD | -210.28% |
| 2014 FY | -17.97 Million USD | -197.22% |
| 2014 Q4 | -5.5 Million USD | 39.52% |
| 2014 Q2 | -2.93 Million USD | -9.3% |
| 2014 Q1 | -2.68 Million USD | 17.54% |
| 2013 Q2 | 754.57 Thousand USD | 115.71% |
| 2013 Q1 | -4.8 Million USD | -93.51% |
| 2013 Q3 | 483.32 Thousand USD | -35.95% |
| 2013 FY | -6.04 Million USD | 68.79% |
| 2013 Q4 | -3.25 Million USD | -773.48% |
| 2012 Q3 | -5.19 Million USD | 0.0% |
| 2012 Q4 | -2.48 Million USD | 52.23% |
| 2012 FY | -19.38 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 125.518% |
| PainReform Ltd. | -9.34 Million USD | 481.443% |
| Alvotech | -551.73 Million USD | 106.46% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 25.985% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -89.797% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 552.884% |
| Journey Medical Corporation | -3.85 Million USD | 1025.045% |
| Dynavax Technologies Corporation | -6.38 Million USD | 657.865% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 117.033% |
| Bright Green Corporation | -13.12 Million USD | 371.503% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 15.047% |
| Embecta Corp. | 70.4 Million USD | 49.372% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 890.982% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 890.982% |
| SCYNEXIS, Inc. | 67.04 Million USD | 46.836% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 536.619% |
| Silver Spike Investment Corp. | 7.34 Million USD | -385.579% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 1250.287% |
| Alpha Teknova, Inc. | -36.78 Million USD | 196.906% |
| Safety Shot Inc | -15.08 Million USD | 336.305% |
| Procaps Group, S.A. | 42.54 Million USD | 16.215% |
| Cosmos Health Inc. | -18.54 Million USD | 292.216% |
| Theratechnologies Inc. | -23.95 Million USD | 248.775% |
| Harrow Health, Inc. | -24.41 Million USD | 246.008% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 837.166% |
| Biofrontera Inc. | -20.13 Million USD | 277.05% |
| DURECT Corporation | -27.62 Million USD | 229.025% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -2608.359% |
| Cronos Group Inc. | -73.96 Million USD | 148.189% |
| OptiNose, Inc. | -35.48 Million USD | 200.448% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 103.556% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 184.462% |
| RedHill Biopharma Ltd. | 23.91 Million USD | -49.03% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -620.768% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -22453.517% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 667.609% |
| Radius Health, Inc. | -25.79 Million USD | 238.195% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 678.317% |
| ProPhase Labs, Inc. | -16.78 Million USD | 312.382% |
| Phibro Animal Health Corporation | 2.41 Million USD | -1375.248% |
| Procaps Group S.A. | 42.54 Million USD | 16.215% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 446.78% |
| Viatris Inc. | 54.7 Million USD | 34.841% |
| Rockwell Medical, Inc. | -8.43 Million USD | 522.349% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 324.956% |
| SIGA Technologies, Inc. | 68.06 Million USD | 47.638% |
| Tilray Brands, Inc. | -244.98 Million USD | 114.549% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -196.695% |
| Shineco, Inc. | -22.44 Million USD | 258.769% |
| PetIQ, Inc. | 2.13 Million USD | -1572.548% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 928.53% |
| Incannex Healthcare Limited | -18.45 Million USD | 293.087% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 85.726% |
| Alimera Sciences, Inc. | -20.13 Million USD | 277.042% |
| Assertio Holdings, Inc. | -331.94 Million USD | 110.737% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 640.626% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 299.128% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 277.701% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 122.238% |
| Hempacco Co., Inc. | -13.12 Million USD | 371.536% |
| Talphera, Inc. | -18.39 Million USD | 293.738% |
| Alvotech | -551.73 Million USD | 106.46% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 89.089% |
| Currenc Group, Inc. | -15.3 Million USD | 332.855% |
| Kamada Ltd. | 8.28 Million USD | -330.251% |
| Indivior PLC | 2 Million USD | -1682.1% |
| Evoke Pharma, Inc. | -7.79 Million USD | 557.401% |
| Flora Growth Corp. | -57.03 Million USD | 162.49% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 277.701% |
| Evolus, Inc. | -61.68 Million USD | 157.781% |
| HUTCHMED (China) Limited | 100.78 Million USD | 64.634% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 74.087% |
| Akanda Corp. | -32.27 Million USD | 210.432% |